New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) — Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has appointed prominent sports medical professional Michael Milligan, MD, MBA, as its Chief Medical Officer.
Dr. Milligan is fellowship-trained and certified in sports medicine and board-certified in family medicine. He brings more than 25 years of clinical, leadership, and research experience, with extensive expertise in sports injuries and musculoskeletal and orthopedic medicine.
“As medical science continues to improve how we extend both lifespan and quality of life, more people are taking an active interest in their long-term health,” said Dr. Michael Milligan, MD, MBA, Chief Medical Officer of Human Continuum. “I am very pleased to join Dr. Law and Dr. Sial and to apply my decades of clinical and research experience toward advancing extracellular vesicle-based therapeutics and topical formulations. The scientific potential of this technology is significant, and I am excited to contribute to advancing solutions that support healthier, longer lives alongside the Human Continuum team.”
Currently, Dr. Milligan is program director for primary sports medicine, regenerative medicine, and for business strategy for HSS Florida. Prior to joining HSS FL, he was program director of primary care sports medicine and medical director of sports medicine outreach for the Andrews Institute in Pensacola, Florida. During his time at the Andrews Institute Dr. Milligan led numerous initiatives including value metric based health care programs, service line coordination to improve viability during implementation of the CMS bundled payment program for joint replacement, and development of an integrated multidisciplinary spine program.
Figure 1 – Human Continuum Inc. Appoints Dr. Michael Milligan, MD, MBA, as its Chief Medical Officer.
Dr. Milligan came to the Andrews Institute after a decade in college athletics serving as the Head Team Physician and Medical Director of all athletic programs at University of Nevada Las Vegas and later as the Head Team Physician and Medical Director of Northwestern University Athletics and Health Services Sports Medicine. During his tenure in Division I collegiate athletics, Dr. Milligan served as the primary physician overseeing all athlete healthcare while also leading the development of innovative programs within and beyond the athletic environment, including wellness initiatives, research projects, and performance optimization efforts. He was also a member of the Department of Orthopedics and Northwestern Medicine and a member of the Department of Family Medicine at the University of Nevada School of Medicine Las Vegas.
In the realm of scholarly works, Dr. Milligan served on the IRB (Institutional Review Board) at UNLV, led the early development of the UNLV sports performance lab, has served as editor for peer reviewed journals, spoken across the country at medical conferences, and participated in varying roles on numerous studies and publications.
“I am very pleased to welcome Dr. Milligan to the team,” said Dr. Sean Law, MD, MBA, Chief Executive Officer and Board Member of Human Continuum. “Dr. Milligan’s hands-on clinical experience, particularly in working with high-performance athletes, brings valuable insight into musculoskeletal health, recovery science, and performance optimization. That perspective will be instrumental as we advance extracellular vesicle–based therapeutics aimed at enhancing long-term health and quality of life for all.”
Human Continuum’s mission is to advance next-generation biologic solutions that address a variety of health issues through innovation in exosome therapies. By harnessing the regenerative signaling potential of platelet-derived exosomes, the Company aims to deliver a minimally invasive, scalable, and standardized platform for systemic rejuvenation and inflammation management, setting a new benchmark in longevity-focused care.
About Human Continuum Inc.
Human Continuum Inc. is developing a platform of exosome-based therapeutics and diagnostics spanning longevity, orthopedics, aesthetics, and dermatology. Our lead program is an investigational IV infusion of standardized, cell-free, platelet-derived exosomes designed to deliver regenerative signals that may help modulate systemic inflammation and support cellular health.
Beyond IV infusion, we are advancing:
- Injectable hydrogel–exosome candidates for musculoskeletal conditions (e.g., osteoarthritis, tendon and ligament injuries), engineered for localized, sustained delivery.
- Topical plant-derived exosome formulations for skin appearance and barrier support, with scalable isolation and QC built for consumer and clinic settings.
- Point-of-care diagnostics for rapid joint-infection detection using synovial-fluid exosomal biomarkers.
- Exosomal biomarker panels to aid early diagnosis and longitudinal monitoring of orthopedic disease.
For more corporate information please visit: humancontinuum.com
For further Human Continuum information, please contact:
Email: [email protected]
Business Tel: 877-484-8626
PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:
Human Continuum LINKEDIN
Human Continuum X
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve known and unknown risks, uncertainties and other factors, which may be beyond our control. For Human Continuum Inc., particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following which are, and will be, exacerbated by any worsening of global business and economic environment: (i) risks related to the development of new or advanced technology, including difficulties with design and testing, cost overruns, development of competitive technology, loss of key individuals and uncertainty of success of patent filing, (ii) our ability to obtain contracts and funding to be able to continue operations and (iii) risks related to uncertainty regarding our ability to commercially deploy a competitive platform of exosome-based therapeutics and diagnostics spanning longevity, orthopedics, aesthetics, and dermatology, (iv) risks related to the impact of government regulation and policies including by the FDA; and other risks and uncertainties discussed in this and our other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
